So looks to be a combination of good news in TRT research out of Europe, as well as a bunch of short sellers getting sprung and having to buy out of their positions.
I guess the question is where to from here?
The fundamentals for Acrux still look good, with the technical looking ok now as well.
Given the already ridiculously long list of assosciated risks with testosterone replacement therapy, I really doubt this recent round of fear mongering will affect Axiron's sales for an extended period. I think its evident that the lack of testosterone probably does more harm than having a balanced level.
Please make sure to keep in mind the troubles Viagra had getting off the ground, however it has now a giant recognizable worldwide drug!
ACR Price at posting:
$1.25 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)